<SEC-DOCUMENT>0001712641-25-000003.txt : 20250918
<SEC-HEADER>0001712641-25-000003.hdr.sgml : 20250918
<ACCEPTANCE-DATETIME>20250918115926
ACCESSION NUMBER:		0001712641-25-000003
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250916
FILED AS OF DATE:		20250918
DATE AS OF CHANGE:		20250918

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Biofrontera AG
		CENTRAL INDEX KEY:			0001712641
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40943
		FILM NUMBER:		251322285

	BUSINESS ADDRESS:	
		STREET 1:		HEMMELRATHER WEG 201
		CITY:			LEVERKUSEN
		STATE:			2M
		ZIP:			D-51377
		BUSINESS PHONE:		011 49 214 876 00

	MAIL ADDRESS:	
		STREET 1:		HEMMELRATHER WEG 201
		CITY:			LEVERKUSEN
		STATE:			2M
		ZIP:			D-51377

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biofrontera Inc.
		CENTRAL INDEX KEY:			0001858685
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				473765675
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		781-245-1325

	MAIL ADDRESS:	
		STREET 1:		120 PRESIDENTIAL WAY,
		STREET 2:		SUITE 330
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-09-16</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001858685</issuerCik>
        <issuerName>Biofrontera Inc.</issuerName>
        <issuerTradingSymbol>BFRI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001712641</rptOwnerCik>
            <rptOwnerName>Biofrontera AG</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>HEMMELRATHER WEG 201</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>LEVERKUSEN</rptOwnerCity>
            <rptOwnerState>2M</rptOwnerState>
            <rptOwnerZipCode>D-51377</rptOwnerZipCode>
            <rptOwnerStateDescription>GERMANY</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Series D Convertible Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.0006</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-09-16</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>3019</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>4831172</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>3019</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.</footnote>
        <footnote id="F2">The reporting person acquired the convertible preferred stock in a privately negotiated transaction in exchange for assets related to the production and sale of certain products in the United States having an estimated market value of approximately $3,019,000.</footnote>
    </footnotes>

    <remarks>The Reporting Person has entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer.  Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer.  By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer.  Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.</remarks>

    <ownerSignature>
        <signatureName>/s/ Maria del Pilar de la Huerta Martinez, as Chief Financial Officer of Biofrontera AG</signatureName>
        <signatureDate>2025-09-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
